Novomer, Inc.

Novomer Set to Continue Strong Momentum with New CEO and Corporate Headquarters in Massachusetts

Novomer Set to Continue Strong Momentum with New CEO and Corporate Headquarters in Massachusetts

October 20, 2008

Former Surface Logix CEO, Jim Mahoney, Joins to Spearhead Growth

Novomer, Inc.

Novomer Names Industry Veteran Peter Shepard as Vice President of Business Development

Novomer Names Industry Veteran Peter Shepard as Vice President of Business Development

October 20, 2008

Shepard Brings More than 25 Years of Specialty Chemical and Polymer Industry Experience to Novomer

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential for Once Daily Dosing of Novel Oxazolidinone Antibiotic

Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential for Once Daily Dosing of Novel Oxazolidinone Antibiotic

October 27, 2008

Findings Presented at ICAAC/IDSA

Quanterix Corporation

Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board

Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board

November 11, 2008

CAMBRIDGE, Mass., Nov. 11 /PRNewswire/ -- Quanterix Corporation, the leader in single molecule detection, announced today that Robert Corn, Ph.D. has joined its Scientific Advisory Board (SAB). Dr. Corn is a Professor in the Departments of Chemistry and Biomedical Engineering at the University of California, Irvine. Dr. Corn's primary research areas include the development of new methods for detecting binding of biomolecules to surfaces and chemical modification strategies to control specific and non-specific adsorption of biopolymers to a variety of surfaces.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Announces Open IND for RX-10045, the Lead Resolvin Therapeutic for Dry Eye

Resolvyx Announces Open IND for RX-10045, the Lead Resolvin Therapeutic for Dry Eye

November 20, 2008

Resolvyx to Initiate Phase 1/2 Clinical Trial with RX-10045 in Patients with Dry Eye

Accuri Cytometers, Inc.

Accuri Announces Sale of 500th C6 Flow Cytometer® System and Award Of Two Free Units for Innovative Flow Cytometry Applications

Accuri Announces Sale of 500th C6 Flow Cytometer® System and Award Of Two Free Units for Innovative Flow Cytometry Applications

May 6, 2010

2010 Creativity Awards Program Recipients Plan Diverse Applications Including Food Safety Monitoring and Analysis of Blood Platelet Disorders

Rapid Uptake by Scientists Worldwide Is Testament to the Mix of Performance, Ease-of-Use and Cost-Effectiveness of the Accuri C6 Flow Cytometer

Learn More about the Accuri C6 Flow Cytometer System at CYTO 2010 & Immunology 2010

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team

Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team

November 24, 2008

Drs Chi Dang, Joshua Rabinowitz, Clary Clish, Matthew Vander Heiden and James Bradner Bring Deep Biology and Metabolomic Experience from Leading Laboratories

Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel
drugs in the rapidly emerging field of cancer metabolism, announced today the appointments of several leading scientific advisors:

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Expands Into 21,000 SqFt Facility

Agios Pharmaceuticals Expands Into 21,000 SqFt Facility

November 24, 2008

Creates Largest Research Laboratory Dedicated to Cancer Metabolism

Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today that it has leased a 21,000 square-foot facility in Cambridge. This new facility creates the world’s largest laboratory dedicated to cancer metabolism research.

Ze-gen, Inc.

Terry Newendorp Joins Ze-gen’s Board of Directors

Terry Newendorp Joins Ze-gen’s Board of Directors

December 18, 2008

Boston, MA – December 18, 2008 Ze-gen, Inc., a clean energy company providing advanced gasification technology to convert waste streams into synthesis gas, is pleased to announce the addition of Terry Newendorp to its Board of Directors.

Helicos BioSciences Corporation

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

December 19, 2008

CAMBRIDGE, Mass., Dec 19, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain investors to raise approximately $18.6 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.